dc.contributor.author |
Nash, T.E. |
|
dc.contributor.author |
Mahanty, S. |
|
dc.contributor.author |
García Lescano, Héctor Hugo |
|
dc.date.accessioned |
2022-01-18T19:34:40Z |
|
dc.date.available |
2022-01-18T19:34:40Z |
|
dc.date.issued |
2011 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12866/11123 |
|
dc.description.abstract |
The cystic larvae of Taenia solium commonly infect the human nervous system, resulting in neurocysticercosis, a major contributor to seizure disorders in most of the world. Inflammation around the parasites is a hallmark of neurocysticercosis pathophysiology. Although mechanisms regulating this inflammation are poorly understood, anti-inflammatory drugs, particularly corticosteroids, have been long used alone or with anthelmintics to manage disease and limit neurological complications and perhaps damage to neural tissues. Only scarce controlled data exist to determine when and what type of corticosteroids and the treatment regime to use. This article revisits the mechanisms of action, rationale, evidence of benefit, safety and problems of corticosteroids in the context of neurocysticercosis, as well as alternative anti-inflammatory strategies to limit the damage caused by inflammation in the CNS. |
en_US |
dc.language.iso |
eng |
|
dc.publisher |
Taylor and Francis |
|
dc.relation.ispartofseries |
Expert Review of Neurotherapeutics |
|
dc.rights |
info:eu-repo/semantics/restrictedAccess |
|
dc.rights.uri |
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es |
|
dc.subject |
Humans |
en_US |
dc.subject |
Animals |
en_US |
dc.subject |
review |
en_US |
dc.subject |
azathioprine |
en_US |
dc.subject |
drug blood level |
en_US |
dc.subject |
drug dose reduction |
en_US |
dc.subject |
drug megadose |
en_US |
dc.subject |
inflammation |
en_US |
dc.subject |
low drug dose |
en_US |
dc.subject |
methotrexate |
en_US |
dc.subject |
side effect |
en_US |
dc.subject |
gamma interferon |
en_US |
dc.subject |
weight gain |
en_US |
dc.subject |
interleukin 1beta |
en_US |
dc.subject |
albendazole |
en_US |
dc.subject |
treatment duration |
en_US |
dc.subject |
interleukin 2 |
en_US |
dc.subject |
interleukin 4 |
en_US |
dc.subject |
interleukin 5 |
en_US |
dc.subject |
interleukin 6 |
en_US |
dc.subject |
interleukin 8 |
en_US |
dc.subject |
tumor necrosis factor alpha |
en_US |
dc.subject |
Taenia solium |
en_US |
dc.subject |
taeniasis |
en_US |
dc.subject |
diabetes mellitus |
en_US |
dc.subject |
Anthelmintics |
en_US |
dc.subject |
cysticercosis |
en_US |
dc.subject |
praziquantel |
en_US |
dc.subject |
drug safety |
en_US |
dc.subject |
pathogenesis |
en_US |
dc.subject |
Neurocysticercosis |
en_US |
dc.subject |
albendazole sulfoxide |
en_US |
dc.subject |
methylprednisolone |
en_US |
dc.subject |
drug mechanism |
en_US |
dc.subject |
immune response |
en_US |
dc.subject |
dexamethasone |
en_US |
dc.subject |
drug withdrawal |
en_US |
dc.subject |
treatment withdrawal |
en_US |
dc.subject |
life cycle |
en_US |
dc.subject |
interleukin 12 |
en_US |
dc.subject |
anticonvulsive agent |
en_US |
dc.subject |
seizure |
en_US |
dc.subject |
corticosteroid therapy |
en_US |
dc.subject |
brain calcification |
en_US |
dc.subject |
Adrenal Cortex Hormones |
en_US |
dc.subject |
Anti-Inflammatory Agents |
en_US |
dc.subject |
aseptic necrosis |
en_US |
dc.subject |
brain edema |
en_US |
dc.subject |
Central Nervous System |
en_US |
dc.subject |
corticosteroids |
en_US |
dc.subject |
cycloheximide |
en_US |
dc.subject |
cyclooxygenase 2 |
en_US |
dc.subject |
endothelial leukocyte adhesion molecule 1 |
en_US |
dc.subject |
folic acid |
en_US |
dc.subject |
hip disease |
en_US |
dc.subject |
hydrocephalus |
en_US |
dc.subject |
inducible nitric oxide synthase |
en_US |
dc.subject |
interleukin 18 |
en_US |
dc.subject |
monocyte chemotactic protein 1 |
en_US |
dc.subject |
prednisolone |
en_US |
dc.subject |
seizures |
en_US |
dc.subject |
vascular cell adhesion molecule 1 |
en_US |
dc.title |
Corticosteroid use in neurocysticercosis |
en_US |
dc.type |
info:eu-repo/semantics/review |
|
dc.identifier.doi |
https://doi.org/10.1586/ern.11.86 |
|
dc.subject.ocde |
https://purl.org/pe-repo/ocde/ford#3.01.04 |
|
dc.subject.ocde |
https://purl.org/pe-repo/ocde/ford#3.01.05 |
|
dc.relation.issn |
1744-8360 |
|